MedTrace Logo

C-peptide Concentrations in Type 2 Diabetes Treated With Insulin; is it Time to Revise the Treatment of Type 2 Diabetes

NCT04005261 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 249

Last updated 2019-07-02

No results posted yet for this study

Summary

C-peptide is used to evaluate beta cell reserves. Patients with type 2 diabetes are treated with insulin for different indications. Other than beta-cell insufficiency and organ failures, insulin treatment is needed for a specified period. The investigators want to evaluate beta cell reserves in patients with type 2 diabetes treated with insulin for at least six months to see if that is the case. The investigators also want to compare the characteristics of these patients according to their beta cell reserves.

Conditions

  • Type 2 Diabetes Treated With Insulin

Interventions

DIAGNOSTIC_TEST

C-peptide concentrations

The patients will be grouped by their C-peptide concentrations

Sponsors & Collaborators

  • Goztepe Training and Research Hospital

    lead OTHER

Principal Investigators

  • Ayşe N Erbakan, MD · IMU Doctoral program

  • Mehmet Uzunlulu, Prof · IMU Goztepe Education and Research Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-01
Primary Completion
2019-02-01
Completion
2019-03-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04005261 on ClinicalTrials.gov